aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees for an aggregate of 12,200 shares. These grants, made under Nasdaq Listing Rule 5635(c)(4), are an inducement for their employment. The options vest over four years, with a 25% initial vest and monthly installments thereafter.
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma, Inc. announced that its Compensation Committee granted nonstatutory stock options to two new employees. These options allow them to purchase a total of 12,200 shares of common stock at $0.98 per share, effective February 17, 2026. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the aTyr Pharma, Inc. 2022 Inducement Plan, vesting over four years.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma announced that its Compensation Committee granted nonstatutory stock options to two new employees to purchase an aggregate of 12,200 shares of common stock. These grants, with an exercise price of $0.98 per share, were made as an inducement for employment under Nasdaq Listing Rule 5635(c)(4) and vest over four years, subject to continued employment.
Final visit completed in Phase 3 EFZO-FIT clinical trial of efzofitimod
The Phase 3 EFZO-FIT clinical trial for Atyr Pharma’s experimental treatment, efzofitimod, for pulmonary sarcoidosis has completed its final patient visit. Top-line results are anticipated in the third quarter of this year. Efzofitimod aims to reduce inflammation and scarring by targeting activated myeloid cells, potentially offering a steroid-sparing treatment option to improve the quality of life for patients.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, a clinical stage biotechnology company, announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference on March 11, 2026. The presentation will cover the company's progress in developing first-in-class medicines from its proprietary tRNA synthetase platform, including its lead therapeutic candidate, efzofitimod, for interstitial lung disease. Management will also be available for one-on-one meetings with investors.
Biotech aTyr Pharma CEO to speak at Miami global healthcare conference
aTyr Pharma (Nasdaq: ATYR) announced that its President and CEO, Sanjay S. Shukla, will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026. The presentation will cover corporate updates, and management will also be available for one-on-one meetings with registered investors. A live webcast and replay will be accessible on the company's website.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, Inc. announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference on March 11, 2026. The company, a clinical-stage biotechnology firm, specializes in developing therapies for fibrosis and inflammation using its proprietary tRNA synthetase platform. Management will also be available for one-on-one meetings with investors, and a webcast will be available on the company's website.
aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings
Insiders at aTyr Pharma, Inc. have significantly increased their stock holdings over the last year, with an Independent Director making a large US$912k purchase near the current share price. This indicates increased optimism about the company's future prospects, despite relatively low overall insider ownership (2.5%). While there haven't been recent insider transactions, the past year's buying activity is seen as an encouraging sign.
The Truth About aTyr Pharma Inc (LIFE): Tiny Stock, Huge Bets – But Is It Worth the Hype?
This article provides an in-depth look at aTyr Pharma Inc (LIFE), a clinical-stage biotech company, analyzing its stock performance, scientific focus, and market hype. It highlights the high-risk, high-reward nature of investing in LIFE due to its experimental pipeline targeting lung and immune disorders. The author advises caution, noting the stock's extreme volatility and dependence on clinical trial success for long-term investors.
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth by 2034, driven by increasing prevalence and the launch of new pipeline products. Key players like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics are developing therapies, with Avidity Biosciences showing promising clinical trial results for delpacibart braxlosiran, and Epicrispr Biotechnologies receiving IND clearance for its epigenetic-based treatment, EPI-321. The report highlights that the US accounts for a substantial portion of FSHD cases, and there's a high demand for effective treatments as no approved therapies currently exist.
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected
This week in biotech, aTyr Pharma scheduled an FDA meeting for its Efzofitimod program, while Aquestive Therapeutics received a Complete Response Letter for its Anaphylm application. Sangamo Therapeutics reported positive data from its Fabry disease study, and Novo Nordisk announced strong results for CagriSema in Type 2 Diabetes. Sanofi's Venglustat met primary goals in a Gaucher study but fell short in a Fabry disease trial.
Atyr Pharma CEO Shukla sells $3.6k in stock
Atyr Pharma CEO Shukla Sanjay sold 3,745 shares of common stock for $3,655 to cover tax obligations related to vested restricted stock units. This occurred after acquiring 10,375 shares from RSU vesting, bringing his total direct ownership to 153,553 shares. Separately, aTyr Pharma received FDA acceptance for a Type C meeting in mid-April 2026 to discuss their lead therapeutic candidate, efzofitimod, for pulmonary sarcoidosis.
Atyr Pharma CFO Broadfoot sells $1.5k in stock
Atyr Pharma's CFO, Jill Marie Broadfoot, sold 1,558 shares of common stock for approximately $1,520 after restricted stock units vested. This transaction occurred just before the company announced that the FDA accepted its request for a Type C meeting in mid-April 2026 to discuss efzofitimod for pulmonary sarcoidosis, following positive Phase 3 study results.
aTyr Pharma general counsel sells $1091 in stock
Nancy Denyes, General Counsel at aTyr Pharma INC (NASDAQ:ATYR), sold 1,118 shares of common stock for $1,091 on February 4, 2026. This transaction follows the vesting of restricted stock units and occurs amidst the company's financial challenges and a significant stock price drop over the past year. aTyr Pharma also announced FDA acceptance for a meeting to discuss efzofitimod, a therapeutic candidate for pulmonary sarcoidosis.
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting
aTyr Pharma (NASDAQ:ATYR) announced that the FDA has accepted its request for a Type C meeting in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis. While the primary endpoint was not met, secondary measures showed benefits. The company's stock has seen a 37% return over the past week and nearly 24% year-to-date, despite a significant decline over the past year and negative EBITDA.
aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ)
aTyr Pharma will meet with the FDA in April to discuss the future of its lead drug candidate, efzofitimod, for lung disease. The company's shares fell approximately 8% on Tuesday following the announcement. This meeting is crucial for determining the path forward for the drug.
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
aTyr Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted its meeting request to discuss its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis. The Type C meeting is scheduled for mid-April 2026. The company anticipates providing an update on the meeting's outcome after receiving the official minutes.
aTyr Pharma (ATYR) Prepares for Key FDA Meeting on Efzofitimod
aTyr Pharma (ATYR) is preparing for a crucial FDA Type C meeting in mid-April 2026 to discuss its therapeutic candidate, efzofitimod, for pulmonary sarcoidosis. The company will review the results of its Phase 3 EFZO-FIT study to determine the next steps for approval. Despite financial challenges and significant losses, aTyr Pharma maintains a strong liquidity position, although its valuation metrics suggest potential overvaluation while analyst sentiment remains cautiously optimistic.
FDA sets April meeting on lung sarcoidosis drug efzofitimod trial
aTyr Pharma announced that the FDA has accepted its request for a Type C meeting in mid-April 2026 to discuss the efzofitimod program for pulmonary sarcoidosis. The meeting will review results from the Phase 3 EFZO-FIT study, which did not meet its primary endpoint but showed statistically significant benefits in patient-reported outcomes. The company plans to provide an update on the regulatory path following the meeting.
aTyr Pharma Schedules FDA Meeting to Discuss Phase 3 EFZO-FIT™ Study Results for Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma has scheduled a Type C meeting with the FDA in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis. Although the study did not meet its primary endpoint for corticosteroid dosage reduction, it showed clinical benefits in several secondary measures like quality of life and fatigue scores, and maintained lung function with a good safety profile. The company expects to provide an update on the development path for efzofitimod after the meeting.
FDA to review aTyr Pharma’s efzofitimod data in mid-April meeting
aTyr Pharma announced that the FDA has accepted its request for a Type C meeting in mid-April 2026 to discuss efzofitimod, their lead therapeutic candidate for pulmonary sarcoidosis. The company will review Phase 3 EFZO-FIT study results, which showed benefits in secondary measures despite not meeting the primary endpoint of reducing corticosteroid dosage. This meeting is crucial for the company, which is currently burning through cash, to determine the next steps for the drug's development.
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
aTyr Pharma has announced that the FDA has accepted its request for a Type C meeting to discuss efzofitimod for the treatment of pulmonary sarcoidosis. The meeting is scheduled for mid-April 2026, where the company will review the results of its Phase 3 EFZO-FIT™ study and determine the path forward for the therapeutic candidate. While the study did not meet its primary endpoint, clinical benefits were observed across multiple efficacy parameters.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Brokerages
aTyr Pharma (NASDAQ:ATYR) has received a "Hold" consensus recommendation from seven brokerage firms, with an average 12-month target price of $23.25. The company recently reported weaker-than-expected quarterly earnings and revenue. Despite high institutional ownership, a "sell" rating was reiterated by one firm, and analysts project negative EPS for the current year.
Federated Hermes Inc. Sells 4,122,163 Shares of aTyr Pharma, Inc. $ATYR
Federated Hermes Inc. significantly reduced its stake in aTyr Pharma (NASDAQ:ATYR) by selling over 4.1 million shares, cutting its position by 28.1%. This divestment brings Federated Hermes' total holdings in aTyr Pharma to just over 10.5 million shares, representing a 10.76% stake in the company. The reduction comes as aTyr Pharma reported a third-quarter earnings and revenue miss, with the stock currently trading at approximately $0.88.
Short Interest in aTyr Pharma, Inc. (NASDAQ:ATYR) Drops By 14.7%
Short interest in aTyr Pharma (NASDAQ:ATYR) decreased by 14.7% in January, totaling 21,334,051 shares, which represents about 22.6% of the stock. Institutional investors hold 61.72% of the company's shares. Wall Street analysts currently give ATYR a "Hold" rating with an average price target of $23.25, significantly higher than its current trading price of approximately $0.88.
aTyr Pharma, Inc. (NASDAQ:ATYR) Sees Significant Drop in Short Interest
aTyr Pharma (NASDAQ:ATYR) experienced a 17.7% drop in short interest during December, with 25,013,857 shares shorted by December 31st. This represents about 26.5% of the company's shares and a short-interest ratio of 11.1 days. Several institutional investors also modified their holdings, with major firms like CalSTRS and Prudential initiating new positions, bringing total institutional ownership to 61.72%.
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of "Hold" from Analysts
Eight research firms have given aTyr Pharma (NASDAQ:ATYR) an average rating of "Hold," with a 12-month average price target of $23.25. The company's shares are currently trading near $0.73, and it recently reported quarterly EPS of ($0.26) and revenue of $0.19 million, missing analyst estimates. Institutional investors own a significant portion of the stock, with several firms increasing their stakes.
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Johnson Fistel, PLLP is investigating potential derivative claims against aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches related to disclosures about its Phase 3 EFZO-FIT clinical trial. The investigation focuses on whether the company and executives made false or misleading statements regarding the trial's design and likelihood of success, leading to a significant stock price drop. Shareholders who held shares before November 7, 2024, may have grounds for derivative claims.
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Hold" by Brokerages
aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus "Hold" rating from eight brokerages, with an average one-year price target of $23.25. Despite recent insider buying by Director Paul Schimmel and increased holdings by institutional investors like Vanguard and UBS, the company missed its quarterly EPS and revenue estimates. Shares are currently trading around $0.78 with a market capitalization of approximately $76 million.
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
The Gross Law Firm has announced a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR), notifying investors who purchased shares between November 7, 2024, and September 12, 2025, of an upcoming deadline to register as lead plaintiff. The lawsuit alleges that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to help patients taper off steroid usage. This alleged deception led to a significant stock price decline after the EFZO-FIT study failed to meet its primary endpoint in September 2025.
ATYR LAWSUIT ALERT: Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors - Lead Plaintiff Deadline December 8, 2025
Levi & Korsinsky LLP has issued a lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding a class action securities lawsuit. The lawsuit alleges that aTyr Pharma made false and misleading statements about the efficacy of its drug Efzofitimod, leading to an 83.2% stock price decline after the EFZO-FIT study failed to meet its primary endpoint. Investors who suffered losses between November 7, 2024, and September 12, 2025, are encouraged to learn about their rights to potentially recover losses, with a lead plaintiff deadline of December 8, 2025.
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Johnson Fistel, PLLP is investigating potential derivative claims against aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches related to disclosures about its Phase 3 EFZO-FIT clinical trial. The investigation focuses on claims that aTyr and certain executives made misleading statements regarding the trial's design, its likelihood of meeting the primary endpoint, and the drug's ability to eliminate steroid use. This follows a significant drop in the company's stock price after negative Phase 3 trial results.
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) shareholders for alleged fiduciary breaches. The investigation focuses on disclosures related to the Phase 3 EFZO-FIT clinical trial, where executives allegedly made false or misleading statements about the trial's design, likelihood of success, and the drug's ability to eliminate steroid use. This probe follows a significant drop in the company's stock price after negative Phase 3 trial results.
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors in aTyr Pharma, Inc. (NASDAQ: ATYR) who purchased common stock between January 16, 2025, and September 12, 2025, of the December 8, 2025 deadline to move for lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that the company made false and misleading statements about the efficacy of its drug, Efzofitimod, particularly concerning its ability to help patients completely taper steroid usage. Investors who suffered damages are encouraged to contact the firm to learn more about joining the class action.
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) for shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made misleading statements regarding the efficacy of its drug, Efzofitimod, prior to the announcement that its EFZO-FIT study failed to meet its primary endpoint, leading to an 83.2% stock price decline. Investors are encouraged to contact Levi & Korsinsky before December 8, 2025, to learn about their rights to seek recovery.
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025, and September 12, 2025, of the lead plaintiff deadline on December 8, 2025. The lawsuit alleges that the company made false and misleading statements about the efficacy of its drug Efzofitimod, particularly its ability to allow patients to completely taper steroid usage. Investors who suffered losses have the opportunity to join the class action lawsuit and potentially seek compensation.
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
Rosen Law Firm reminds investors who purchased aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025, and September 12, 2025, of the December 8, 2025, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug Efzofitimod. Investors with losses during this period are encouraged to contact Rosen Law Firm to explore their options.
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
The Gross Law Firm is urging shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR) who suffered losses to join a class action lawsuit. The lawsuit alleges that aTyr Pharma made misleading statements regarding its drug Efzofitimod, particularly its ability for patients to completely taper steroid usage. This claim comes after the EFZO-FIT study failed to meet its primary endpoint, leading to an 83.2% drop in aTyr's stock price on September 15, 2025.
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
The Gross Law Firm is urging shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR) who lost money to join a class action lawsuit. This follows a significant stock price drop after the company announced its EFZO-FIT study did not meet its primary endpoint, allegedly due to misleading statements about the drug Efzofitimod's efficacy. Shareholders have until December 8, 2025, to seek lead plaintiff appointment.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP is investigating potential securities claims against aTyr Pharma, Inc. (NASDAQ: ATYR) and reminds investors of the December 8, 2025 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to fully taper steroid usage, which led to artificially inflated stock prices. Following the release of study results that did not support these claims, aTyr Pharma's stock price dropped significantly.
Shareholders that lost money on aTyr Pharma, Inc.(ATYR)
The Gross Law Firm has issued a notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding a class action lawsuit. The lawsuit alleges that aTyr Pharma made false and misleading statements about the efficacy of Efzofitimod, particularly its ability for patients to completely taper steroid usage, which led to a significant stock price decline when the EFZO-FIT study failed to meet its primary endpoint. Shareholders who purchased ATYR shares between November 7, 2024, and September 12, 2025, are encouraged to contact the firm to learn about potential lead plaintiff appointment before the December 8, 2025 deadline.
New SueWallSt Podcast Covers aTyr Pharma, Inc. (ATYR) Class Action
Levi & Korsinsky, LLP has released a new podcast detailing a class action securities lawsuit against aTyr Pharma, Inc. The lawsuit alleges that aTyr Pharma made false and misleading statements about the efficacy of its drug Efzofitimod, leading to significant investor losses. The company's stock declined by 83.2% after it announced that the EFZO-FIT study did not meet its primary endpoint.
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against aTyr Pharma, Inc. – ATYR
Pomerantz LLP has announced a class action lawsuit against aTyr Pharma, Inc. (NASDAQ:ATYR) on behalf of investors who purchased the company's securities. The lawsuit follows a significant drop in aTyr's stock price after its EFZO-FIT study for Efzofitimod failed to meet its primary endpoint, leading to concerns about securities fraud or unlawful business practices by the company's officers and/or directors. Investors have until December 8, 2025, to seek appointment as Lead Plaintiff.
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm reminds investors of a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) for alleged securities fraud between January 16, 2025, and September 12, 2025. The lawsuit claims aTyr made false and misleading statements regarding its efzofitimod drug's ability to allow patients to completely taper steroid usage. Investors who suffered losses are encouraged to contact the Schall Law Firm to participate in the lawsuit.
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
The Gross Law Firm has announced a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR), notifying investors who purchased shares between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod. This was revealed when the EFZO-FIT study failed to meet its primary endpoint, leading to an 83.2% drop in the company's stock price on September 15, 2025.
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
The Gross Law Firm has issued a notice to investors of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding a class action lawsuit. Shareholders who purchased ATYR shares between November 7, 2024, and September 12, 2025, are encouraged to contact the firm, as the company is accused of making misleading statements about the efficacy of its drug Efzofitimod. The lawsuit stems from the EFZO-FIT study failing to meet its primary endpoint, leading to an 83.2% stock price decline on September 15, 2025.
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
The Gross Law Firm has issued a notice to investors of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding a class action lawsuit. Shareholders who purchased ATYR shares between November 7, 2024, and September 12, 2025, are encouraged to contact the firm, as the company is accused of making misleading statements about its drug Efzofitimod prior to an announcement that the drug's study did not meet its primary endpoint, leading to a significant stock price drop. The deadline to seek lead plaintiff appointment is December 8, 2025.
New SueWallSt Podcast Covers aTyr Pharma, Inc. (ATYR) Class Action
Levi & Korsinsky, LLP has released a podcast regarding a class action securities lawsuit filed against aTyr Pharma, Inc. The lawsuit alleges securities fraud between November 7, 2024, and September 12, 2025, due to misleading statements about the efficacy of Efzofitimod. The stock price declined significantly after the company announced its EFZO-FIT study did not meet its primary endpoint on September 15, 2025.
Lost Money on aTyr Pharma, Inc. (ATYR)? Join Class Action Before December 8, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky LLP has announced a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) for alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to enable patients to taper steroid usage. This follows a significant stock price decline on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
The DJS Law Group is investigating aTyr Pharma, Inc. (NASDAQ: ATYR) for potential securities law violations after its experimental lung disease drug failed to meet its main goal in a late-stage study. This news led to a more than 81% drop in aTyr's stock price on September 15, 2025. Shareholders who suffered losses are encouraged to contact the DJS Law Group for legal consultation.
